N5: Tetrahydro-β-Carboline Mcl-1 Inhibitor Data

Dong-Yuan Ning published data on a novel tetrahydro-β-carboline-derived Mcl-1 inhibitor, designated N5, on figshare in May 2026. The dataset likely contains experimental results for the compound N5 and its hydrochloride N5Y, including binding affinity, selectivity, ADMET properties, and in vivo efficacy. The data describes a compound with antitumor activity and capability to overcome cisplatin resistance in ovarian cancer models.

Use Cases

• Analyze binding affinity and selectivity data for Mcl-1 inhibitors based on the described compound properties
• Evaluate ADMET (absorption, distribution, metabolism, excretion, toxicity) properties for drug candidate screening based on the favorable characteristics mentioned
• Model antitumor efficacy and synergy in combination therapy based on the described in vivo results and cisplatin resistance overcoming capability

Strengths

• Data describes a compound with high binding affinity and selectivity for Mcl-1, as stated in the description
• The dataset includes results for a hydrochloride form (N5Y) with improved antitumor efficacy, as reported

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (3.8 KB), indicating limited scope

Provenance

Source

Dong-Yuan Ning

Collection Method

Likely generated through structure-based drug design (SBDD) and experimental validation

Freshness

Last updated 2026-05-05 15:35:38; freshness should be verified